Navigation Links
Creating a future of personalized medicine: U-M forms joint venture for DNA diagnostics

ANN ARBOR, Mich. and PHOENIX, Ariz. As a key step toward providing patients with treatments based on their own DNA profiles, the University of Michigan and the International Genomics Consortium (IGC) have launched a new joint venture that will help usher in an age of personalized medicine.

Called Paradigm, the new nonprofit company brings together the expertise of the U-M Health System and IGC, two leaders in using genetic information to understand and treat disease.

Beginning with cancer, and then extending into other disease groups, Paradigm will offer doctors and health care organizations anywhere access to whole gene and multi-gene sequencing and molecular diagnostics.

The company will also help support clinical trials at UMHS and other health systems.

Paradigm complements other DNA services offered by UMHS, including the MLabs reference laboratory, and the research-oriented DNA Sequencing Core. Paradigm is being formed under the Michigan Health Corporation, the part of UMHS that enables outside partnerships.

The company will be based in Ann Arbor, with additional operations at IGC headquarters in Phoenix.

"We're thrilled to take this important step that allows us to harness the power of genetic information to guide patient therapy and improve outcomes," says Jay Hess, M.D. Ph.D., M.H.S.A., chair of the Department of Pathology at the U-M Medical School and a co-founder of Paradigm. "IGC has a proven track record of bringing molecular diagnostics to market, yet shares our nonprofit patient-focused vision."

"Paradigm builds on our ever-increasing understanding of the interplay of multiple disease-causing genes and how this affects sensitivity to specific treatment regimens," says Robert Penny, M.D., Ph.D., the chief executive officer and co-founder of Paradigm and IGC, which was formed by veteran genetic researchers and played a key role in compiling The Cancer Genome Atlas, a catalog of genes known to be involved in cancer. "We will bring our expertise to bear to create true personalized medicine options for clinicians and their patients."

Initially, Paradigm will focus on offering services to oncologists and oncology groups, pathologists, academic medical centers and clinical trial groups studying personalized medicine regimens. Its first products will be especially of use in better tailoring treatments for cancer patients.

"Pursuing new, innovative channels for scientific collaboration is a priority and strength of the University of Michigan," notes Ora Pescovitz, M.D., CEO of the U-M Health System and U-M executive vice president for medical affairs. "Paradigm is a terrific example of this effort and of how cutting-edge science will have an immediate benefit for patients."

Contact: Kara Gavin
University of Michigan Health System

Related biology news :

1. 15-year study: When it comes to creating wetlands, Mother Nature is in charge
2. Ultrasound idea: Prototype NIST/CU bioreactor evaluates engineered tissue while creating it
3. Creating energy from light and air - new research on biofuel cells
4. Gecko feet hold clues to creating bandages that stick when wet
5. The future of plant science - a technology perspective
6. The future of plant science a technology perspective
7. Is seaweed the future of biofuel?
8. Algae biofuels: the wave of the future
9. Researchers identify Achilles heel of dengue virus, target for future vaccines
10. Desert to Rainforest global classroom links future teachers, classrooms in Phoenix and Panama
11. New technologies for a blue future
Post Your Comments:
Related Image:
Creating a future of personalized medicine: U-M forms joint venture for DNA diagnostics
(Date:11/19/2015)... 2015  Although some 350 companies are actively involved ... few companies, according to Kalorama Information. These include Roche Diagnostics, ... market share of the 6.1 billion-dollar molecular testing market, ... for Molecular Diagnostic s .    ... controlled by one company and only a handful of ...
(Date:11/17/2015)... Paris from 17 th until ... from 17 th until 19 th November ... has invented the first combined scanner in the world which scans ... Until now two different scanners were required: one for passports ... on the same surface. This innovation is an ideal solution ...
(Date:11/17/2015)... , Nov. 17, 2015 Pressure BioSciences, Inc. ... the development and sale of broadly enabling, pressure cycling ... sciences industry, today announced it has received gross proceeds ... million Private Placement (the "Offering"), increasing the total amount ... or more additional closings are expected in the near ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... , Nov. 24, 2015 /CNW/ - iCo Therapeutics ... today reported financial results for the quarter ended ... expressed in Canadian dollars and presented under International ... United States ," said Andrew Rae ... advancements regarding iCo-008 are not only value enriching ...
(Date:11/24/2015)... ... November 24, 2015 , ... International Society for ... of the premier annual events for pharmaceutical manufacturing: 2015 Annual Meeting. The conference ... ISPE hosted the largest number of attendees in more than a decade. ...
(Date:11/24/2015)... , Nov. 24, 2015  Clintrax Global, Inc., a worldwide provider ... , today announced that the company has set a new ... 391% quarter on quarter growth posted for Q3 of 2014 to ... and Mexico , with the establishment of an ... 2015. --> United Kingdom and ...
(Date:11/24/2015)... PA (PRWEB) , ... November 24, 2015 , ... This ... entrepreneurs at competitive events in five states to develop and pitch their BIG ideas ... projects from each state are competing for votes to win the title of SAP's ...
Breaking Biology Technology: